61 results
8-K
EX-99.1
ACXP
Acurx Pharmaceuticals, Inc.
9 Aug 24
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
7:13am
," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995
8-K
EX-99.1
ACXP
Acurx Pharmaceuticals, Inc.
15 May 24
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
7:13am
forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those
FWP
gaw5 aq29xuv9o9yrf94
2 Apr 24
Free writing prospectus
7:31am
8-K
EX-99.1
4acdtct5z4k 58
18 Mar 24
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
4:15pm
8-K
EX-1.1
irkcgbu1
15 Nov 23
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-99.1
vqisv9 ist
14 Nov 23
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
4:05pm
8-K
m24mna90w
3 Nov 23
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
4:05pm
8-K
EX-99.1
i5l5me
3 Nov 23
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
4:05pm
8-K
EX-99.1
wyv2c0f88tzrvhjj8
2 Oct 23
Other Events
4:41pm
8-K
ey5it
2 Oct 23
Other Events
4:41pm
8-K
EX-99.1
zkhep k1aqt5hzl
14 Aug 23
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
7:10am